Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE) - receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes

Nighttime blood pressure, nighttime glucose values, and target-organ damages in treated type 2 diabetes patients

(2013) Yuichiro Yano et al.   ATHEROSCLEROSIS

Clinical Implications of Cardiovascular Preventing Pleiotropic Effects of Dipeptidyl Peptidase-4 Inhibitors

(2012) Steven G. Chrysant et al.   AMERICAN JOURNAL OF CARDIOLOGY

Glucagon-Like Peptide-1 Receptor Agonist Inhibits Asymmetric Dimethylarginine Generation in the Kidney of Streptozotocin-Induced Diabetic Rats by Blocking Advanced Glycation End Product–Induced Protein Arginine Methyltranferase-1 Expression

(2012) Ayako Ojima et al.   AMERICAN JOURNAL OF PATHOLOGY

Involvement of the Toxic AGEs (TAGE)-RAGE System in the Pathogenesis of Diabetic Vascular Complications: A Novel Therapeutic Strategy

(2012) Masayoshi Takeuchi et al.   CURRENT DRUG TARGETS

Pleiotropic Effects of Glucagon-like Peptide-1 (GLP-1)-Based Therapies on Vascular Complications in Diabetes

(2012) Sho-ichi Yamagishi et al.   CURRENT PHARMACEUTICAL DESIGN

Positive Association Between Serum Level of Glyceraldehyde-Derived Advanced Glycation End Products and Vascular Inflammation Evaluated by [18F]Fluorodeoxyglucose Positron Emission Tomography

(2012) N. Tahara et al.   DIABETES CARE

Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study

(2012) Y. Seino et al.   DIABETES OBESITY & METABOLISM

Glucose-dependent Insulinotropic Polypeptide (GIP) Inhibits Signaling Pathways of Advanced Glycation End Products (AGEs) in Endothelial Cells via its Antioxidative Properties

(2012) A. Ojima et al.   HORMONE AND METABOLIC RESEARCH

Association between sRAGE, esRAGE levels and vascular inflammation: Analysis with 18F-fluorodeoxyglucose positron emission tomography

(2011) Sae Jeong Yang et al.   ATHEROSCLEROSIS

RAGE biology, atherosclerosis and diabetes

(2011) Drazenka Pongrac Barlovic et al.   CLINICAL SCIENCE

Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension

(2011) Yutaka Seino et al.   CURRENT MEDICAL RESEARCH AND OPINION

Total Soluble and Endogenous Secretory Receptor for Advanced Glycation End Products as Predictive Biomarkers of Coronary Heart Disease Risk in Patients With Type 2 Diabetes: An Analysis From the CARDS Trial

(2011) H. M. Colhoun et al.   DIABETES

Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study

(2011) K. Kaku et al.   DIABETES OBESITY & METABOLISM

Soluble receptor for AGE (RAGE) is a novel independent predictor of all-cause and cardiovascular mortality in type 1 diabetes

(2011) M. C. Thomas et al.   DIABETOLOGIA

Sitagliptin Augments Protective Effects of GLP-1 against Advanced Glycation End Product Receptor Axis in Endothelial Cells

(2011) Y. Ishibashi et al.   HORMONE AND METABOLIC RESEARCH

Glucagon-like peptide–1 suppresses advanced glycation end product–induced monocyte chemoattractant protein–1 expression in mesangial cells by reducing advanced glycation end product receptor level

(2011) Yuji Ishibashi et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product–receptor axis

(2011) Takanori Matsui et al.   PHARMACOLOGICAL RESEARCH

The RAGE Axis

(2010) Shi Fang Yan et al.   CIRCULATION RESEARCH

Higher Plasma Soluble Receptor for Advanced Glycation End Products (sRAGE) Levels Are Associated With Incident Cardiovascular Disease and All-Cause Mortality in Type 1 Diabetes

(2010) Johanna W.M. Nin et al.   DIABETES

Revised Equations for Estimated GFR From Serum Creatinine in Japan

(2009) Seiichi Matsuo et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Diagnosis and Classification of Diabetes Mellitus

(2009)   DIABETES CARE

Increased serum HMGB1 level is associated with coronary artery disease in nondiabetic and type 2 diabetic patients

(2008) Xiao Xiang Yan et al.   ATHEROSCLEROSIS

Effect of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Blood Pressure in Nondiabetic Patients With Mild to Moderate Hypertension

(2008) Goutam C. Mistry et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies

(2008) Theodore Mazzone et al.   LANCET

Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes

(2007) Kazuo Nakamura et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS